Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Adenosine Triphosphate and Vitamin B 6

Research Papers that Mention the Interaction

On clinical application of this procedure, it was found that cirrhotic patients without hepatomas could be differentiated from those with primary hepatomas since in the former a clear reduction of AFP levels following the administration of pyridoxine and ATP took place.
Simultaneous injections of pyridoxine and adenosine 5'-triphosphate (ATP) resulted insignificant decreases of elevated serum AFP levels in carbon tetrachloride (CCl4)-injured rats but in 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)-induced hepatoma-bearing rats.
Oncodevelopmental biology and medicine : the journal of the International Society for Oncodevelopmental Biology and Medicine  •  1981  |  View Paper
Importantly, PL and PLP reduced IL-1β production induced by LPS and ATP , or by LPS alone, in mice.
The Journal of Biological Chemistry  •  2016  |  View Paper
Both high- and low-affinity sites for ATP binding in sarcolemmal membranes were also decreased by PLP.
The increase in cardiac contractile activity of isolated heart by ATP was reduced by PLP , unlike propranolol, whereas that by isoproterenol was not depressed by PLP.
Clinical chemistry and laboratory medicine  •  2013  |  View Paper
The allosteric inhibitor, ATP , increased both the accessibility of PLP to iodide and the quantum yield, suggesting induction of a different conformational state which we term I, evidence for which has also been presented by other groups using other probes.
Molecular and Cellular Biochemistry  •  2005  |  View Paper
Pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (3–300 μM), pyridoxal 5phosphate (3–300 μM) and d-tubocurarine (30–300 μM) produced an insurmountable antagonism of responses to ATP , with no marked change in agonist EC50.
Naunyn-Schmiedeberg's Archives of Pharmacology  •  2004  |  View Paper
Furthermore, different concentrations of PLP (1-50 microM) were shown to inhibit the specific ATP gamma S binding at both the high and low affinity sites in the cardiac sarcolemmal membrane; adrenoceptor and Ca2+-channel inhibitors did not affect the ATP-binding.
It is concluded that PLP may antagonize the actions of ATP on the heart in a selective manner and both pyridoxal and phosphate moieties are essential for its action.
We report here that pyridoxal 5'-phosphate (PLP), an active form of vitamin B6, shows antagonism towards ATP-induced positive inotropic effect in … adult cardiomyocytes and ATP-binding in cardiac sarcolemma; ED50 for PLP in each of these cases varied from 10-15 microM. PLP (5-… ATP but … heart.
Journal of molecular and cellular cardiology  •  1999  |  View Paper
Suramin and pyridoxalphosphate‐6‐azophenyl‐2′ , 4′‐disulphonic acid (PPADS), P2 receptor antagonists, failed to inhibit the depression produced by ATP (50 μM).
British journal of pharmacology  •  1998  |  View Paper
These affects of ATP were antagonized by pyridoxal‐phosphate‐6‐azophenyl‐ 2′, 4′‐disulphonic acid (PPADS; 30 μM) but not suramin (100 μM).
British journal of pharmacology  •  1997  |  View Paper
In the presence of 10 μmol 1−1 pyridoxal‐5″‐phosphate or 30 μmol 1−1 suramin, the secretory response to ATP was reduced, but the effect of UTP was unaltered.
British journal of pharmacology  •  1995  |  View Paper
The inhibition of pyridoxal 5'-phosphate for both ATP and Ca2+ was competitive.
The International journal of biochemistry  •  1983  |  View Paper
Show More